Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2010-11-04
2011-10-11
Desai, Rita (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S278000
Reexamination Certificate
active
08034936
ABSTRACT:
Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.
REFERENCES:
patent: 7332519 (2008-02-01), Hinze et al.
patent: 7485634 (2009-02-01), Martin et al.
patent: 7547707 (2009-06-01), Hinze et al.
patent: 7595311 (2009-09-01), Busch et al.
patent: 2005/0192333 (2005-09-01), Hinze et al.
patent: 2006/0004034 (2006-01-01), Hinze et al.
patent: 2006/0235012 (2006-10-01), Davidson et al.
patent: 2007/0149557 (2007-06-01), Collins et al.
patent: 2008/0280942 (2008-11-01), Diaz-Fernandez et al.
patent: 2009/0042866 (2009-02-01), Lennox et al.
patent: 2009/0326218 (2009-12-01), Martin et al.
patent: WO 03/039469 (2003-05-01), None
patent: WO 2004/043967 (2004-05-01), None
patent: WO 2005/066183 (2005-07-01), None
Zaratin, P.F., et al. “Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (−)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)”, vol. 308, No. 2 (2004) pp. 454-461.
Nurulain Zaveri, “Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents”, XP-002393013, Life Sciences 73 (2003) pp. 663-678.
Calo, Girolamo et al., “Pharmacology of nociceptin and its receptor: a novel therapeutic target”, XP-002303597, British Journal of Pharmacology (2000) vol. 129, pp. 1261-1283.
Kotlinska, Jolanta et al., “Orphanin FQ/Nociceptin Inhibits Morphine Withdrawal”, XP-002393014, Life Sciences, (2000) vol. 66, No. 8, pp. 119-123.
Giannuario, Amalia DI., et al. “Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats”, XP-002393015, Neuroscience Letters 272 (1999) pp. 183-186.
Murphy, Niall P., et al. “Orphanin FQ
ociceptin blocks acquisition of morphine place preference” XP-002393016, Brain Research 832 (1999) pp. 168-170.
Bignan, Gilles C., et al. “Recent advances towards the discovery of ORL-1 receptor agonists and antagonists” XP-002393017, Expert Opinion Ther. Patents (2005) pp. 257-388.
Shoblock James R., et al. “The effect of a systemically active ORL-1 agonist, Ro 64/6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference”, XP-002393018, Neuropharmacology 29 (2005) pp. 439-446.
International Search Report dated Aug. 31, 2006 (Four (4) pages).
German Search Report dated Oct. 4, 2005 with an English translation of the pertinent portions (Nine (9) pages).
Ali Ardati et al., “Interaction of [3H] Orphanin FQ and125I-Tyr14-Orphanin FQ with the Orphanin FQ Receptor: Kinetics and Modulation by Cations and Guanine Nucleotides”, The American Society for Pharmacology and Experimental Therapeutics, Molecular Pharmacology, 51:816-824 (1997).
Ulrike Bischoff et al., “Effects of fluoroquinolones on HERG currents”, European Journal of Pharmacology 406 (2000) 341-343, www.elsevier.nl/locate/ejphar.
Bernard A. Schwetz, DVM, Phd., “Labeling Changes for Orlaam”, JAMA, Jun. 6, 2001—vol. 285, No. 21, www.jama.com.
Jiesheng Kang et al., “Interactions of the narcotic /-α-acetylmethadol with human cardiac K+channels”, European Journal of Pharmacology 458 (2003) 25-29, Elsevier.
Alexander N. Katchman et al., “Influence of Opioid Agonists on Cardiac Human Ether-a-go-go related Gene K+Currents”, The Journal of Pharmacology and Experimental Therapeutics, vol. 303, No. 2, 688-694, 2002, The American Society for Pharmacology and Experimental Therapeutics.
Craig A. Kornick et al., “QTc interval prolongation associated with intravenous methadone”, Pain 105 (2003) 499-506.
J. K. Saelens et al., “The Mouse Jumping Test—A Simple Screening Method to Estimate the Physical Dependence Capacity of Analgesics”, Arch. Int. Pharmacodyn. 190, 213-218 (1971).
James R. Weeks et al., “The Cardiovascular Pharmacology of Prostacyclin (PGI2) in the Rat”, Prostaglandins, Apr. 1979, vol. 17, No. 4, pp. 501-513.
Friderichs Elmar
Koegel Babette-Yvonne
Linz Klaus
Crowell & Moring LLP
Desai Rita
Gruenenthal GmbH
LandOfFree
Spirocyclic cyclohexane compounds useful to treat substance... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spirocyclic cyclohexane compounds useful to treat substance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocyclic cyclohexane compounds useful to treat substance... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300715